Xenetic Biosciences Inc - Asset Resilience Ratio
Xenetic Biosciences Inc (XBIO) has an Asset Resilience Ratio of 0.43% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XBIO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2017)
This chart shows how Xenetic Biosciences Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Xenetic Biosciences Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Xenetic Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xenetic Biosciences Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.00K | 0.43% |
| Total Liquid Assets | $67.00K | 0.43% |
Asset Resilience Insights
- Limited Liquidity: Xenetic Biosciences Inc maintains only 0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xenetic Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Xenetic Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Xenetic Biosciences Inc (2014–2017)
The table below shows the annual Asset Resilience Ratio data for Xenetic Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.35% | $67.00K | $19.16 Million | +0.03pp |
| 2016-12-31 | 0.32% | $67.00K | $20.97 Million | -0.08pp |
| 2015-12-31 | 0.40% | $67.00K | $16.91 Million | -0.01pp |
| 2014-12-31 | 0.40% | $66.00K | $16.32 Million | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more